Emmanuel S Antonarakis


Ontology type: schema:Person     


Person Info

NAME

Emmanuel S

SURNAME

Antonarakis

Publications in SciGraph latest 50 shown

  • 2019-03 Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2018-12 Microsatellite instability in prostate cancer by PCR or next-generation sequencing in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-11 Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2018-09-06 Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment in WORLD JOURNAL OF UROLOGY
  • 2018-09 The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2018-06 p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2017-12 A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) in BMC CANCER
  • 2017-03 Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2016-12 Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide in NATURE REVIEWS UROLOGY
  • 2016-12 Sequencing Treatment for Castration-Resistant Prostate Cancer in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2016-12 Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-09 Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2016-07 Medical hospitalizations in prostate cancer survivors in MEDICAL ONCOLOGY
  • 2016-06 PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer in MOLECULAR IMAGING AND BIOLOGY
  • 2016-04 Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer in CURRENT UROLOGY REPORTS
  • 2016-03 The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2016-02 A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study in INVESTIGATIONAL NEW DRUGS
  • 2015-12 Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2015-12 Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-08 AR splice variant dimerization—clinical implications in NATURE REVIEWS UROLOGY
  • 2015-08 Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer in MOLECULAR IMAGING AND BIOLOGY
  • 2015-06 Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2015-03 Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2014-10 Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone in HORMONES AND CANCER
  • 2014-09 Growth factor and signaling pathways and their relevance to prostate cancer therapeutics in CANCER AND METASTASIS REVIEWS
  • 2014-03 The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2014-03 Very-high-risk localized prostate cancer: definition and outcomes in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2014 Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer in MANAGEMENT OF CASTRATION RESISTANT PROSTATE CANCER
  • 2013-04 A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-12 Prostate angiosarcoma: a case report and literature review in MEDICAL ONCOLOGY
  • 2012-09 Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature in JOURNAL OF GASTROINTESTINAL CANCER
  • 2012-03 Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-09 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2011-09 Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2010-05 Update: Immunological Strategies for Prostate Cancer in CURRENT UROLOGY REPORTS
  • 2010-05 Ruthenium-based chemotherapeutics: are they ready for prime time? in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2008-10-28 Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2008-09 Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? in NATURE REVIEWS UROLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.21107.35", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.254444.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411935.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411940.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5386.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16753.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.469474.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.50956.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5600.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.241103.5", 
            "type": "Organization"
          }
        ], 
        "familyName": "Antonarakis", 
        "givenName": "Emmanuel S", 
        "id": "sg:person.01050245067.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050245067.85"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:47", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_523.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01050245067.85'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01050245067.85'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01050245067.85'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01050245067.85'


     

    This table displays all metadata directly associated to this object as RDF triples.

    36 TRIPLES      10 PREDICATES      21 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01050245067.85 schema:affiliation Neb61052e256e445d99df31ccc5afd7f9
    2 https://www.grid.ac/institutes/grid.16753.36
    3 https://www.grid.ac/institutes/grid.241103.5
    4 https://www.grid.ac/institutes/grid.254444.7
    5 https://www.grid.ac/institutes/grid.411935.b
    6 https://www.grid.ac/institutes/grid.411940.9
    7 https://www.grid.ac/institutes/grid.469474.c
    8 https://www.grid.ac/institutes/grid.48336.3a
    9 https://www.grid.ac/institutes/grid.50956.3f
    10 https://www.grid.ac/institutes/grid.5386.8
    11 https://www.grid.ac/institutes/grid.5600.3
    12 schema:familyName Antonarakis
    13 schema:givenName Emmanuel S
    14 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050245067.85
    15 schema:sdDatePublished 2019-03-07T14:47
    16 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    17 schema:sdPublisher N485fe37259f14b66a8af371ec7054ef3
    18 sgo:license sg:explorer/license/
    19 sgo:sdDataset persons
    20 rdf:type schema:Person
    21 N485fe37259f14b66a8af371ec7054ef3 schema:name Springer Nature - SN SciGraph project
    22 rdf:type schema:Organization
    23 Neb61052e256e445d99df31ccc5afd7f9 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
    24 sgo:isCurrent true
    25 rdf:type schema:OrganizationRole
    26 https://www.grid.ac/institutes/grid.16753.36 schema:Organization
    27 https://www.grid.ac/institutes/grid.21107.35 schema:Organization
    28 https://www.grid.ac/institutes/grid.241103.5 schema:Organization
    29 https://www.grid.ac/institutes/grid.254444.7 schema:Organization
    30 https://www.grid.ac/institutes/grid.411935.b schema:Organization
    31 https://www.grid.ac/institutes/grid.411940.9 schema:Organization
    32 https://www.grid.ac/institutes/grid.469474.c schema:Organization
    33 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    34 https://www.grid.ac/institutes/grid.50956.3f schema:Organization
    35 https://www.grid.ac/institutes/grid.5386.8 schema:Organization
    36 https://www.grid.ac/institutes/grid.5600.3 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...